Zelira Therapeutics (ASX:ZLD) Cash-to-Debt : 0.04 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zelira Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.04.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zelira Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zelira Therapeutics's Cash-to-Debt or its related term are showing as below:

ASX:ZLD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 5023.9 Max: No Debt
Current: 0.04

During the past 13 years, Zelira Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.04. And the median was 5023.90.

ASX:ZLD's Cash-to-Debt is ranked worse than
96.72% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs ASX:ZLD: 0.04

Zelira Therapeutics Cash-to-Debt Historical Data

The historical data trend for Zelira Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zelira Therapeutics Cash-to-Debt Chart

Zelira Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

2.69

9.01

5.48

0.33

Zelira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															14.25	5.48	0.27	0.33	0.04

Competitive Comparison of Zelira Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Zelira Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Cash-to-Debt falls into.

Zelira Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zelira Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.146	/	(0.143	+	0.295)
	=	0.33

Zelira Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.065	/	(1.513	+	0.212)
	=	0.04

Zelira Therapeutics (ASX:ZLD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zelira Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics (ASX:ZLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZLDAF:USA G1G:Germany

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines